Epidemiology, clinical manifestation, and disease course of neuromyelitis optica spectrum disorders

Česká verzia

Authors: J. Libertínová
Authors place of work: Neurologická klinika, 2. LF UK a FN Motol, Praha
Published in the journal: Cesk Slov Neurol N 2020; 83/116(supplementum 1): 15-19
doi: https://doi.org/10.14735/amcsnn2020S15

Summary

Neuromyelitis optica (NMO) is an autoimmune disease of the CNS and is characterized by typically acute and severe impairment of the optic nerve and spinal cord. Autoantibodies to aquaporin-4 (aquaporin-4 immunoglobulin G; AQP4-IgG) are serological biomarkers of this disease that are detectable in approximately 80% of patients. The assessment of these antibodies has shown that symptoms of this immune-mediated astrocytopathy are not restricted to the optic nerve and spinal cord. Some patients can develop symptoms and signs due to brainstem, diencephalic, and cerebral involvement. The term NMO spectrum disorders (NMOSD) was coined based on these pieces of knowledge. Epidemiological data on this disease are limited but there are some clear differences to multiple sclerosis that may be most commonly considered in the differential diagnosis. The part of AQP4-IgGnegNMOSD patients might have another type of autoantibodies. These antibodies can target the myelin oligodendrocyte glycoprotein. The characteristics of this group of patients are partially different.

Keywords:

optic neuritis – neuromyelitis optica and neuromyelitis optica spectrum disorders – myelitis – area postrema syndrome

Zdroje

1. Mealy MA, Wingerchuk DM, Greenberg BM et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69 (9): 1176–1180. doi: 10.1001/archneurol.2012.314.

2. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 (9451): 2106–2112. doi: 10.1016/S0140-6736 (04) 17551-X.

3. Asgari N. Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO). Dan Med J 2013; 60 (10): B4730.

4. Asgari N, Lillevang ST, Skejoe HPB et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76 (18): 1589–1595. doi: 10.1212/WNL.0b013e3182190f74.

5. Cossburn M, Tackley G, Baker K et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012; 19 (4): 655–659. doi: 10.1111/j.1468-1331.2011.03529.x.

6. Uzawa A, Mori M, Kuwabara S. Neuromyelitis optica: concept, immunology and treatment. J Clin Neurosci 2014; 21 (1): 12–21. doi: 10.1016/j.jocn.2012.12.022.

7. Nytrová P, Horáková D. Neuromyelitis optica. Cesk Slov Neurol N 2015; 78/111 (2): 130–137. doi: 10.14735/amcsnn2015130.

8. Brum DG, Barreira AA, dos Santos AC et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler 2010; 16 (1): 21–29. doi: 10.1177/1352458509350741.

9. Zéphir A, Fajardy I, Outteryck O et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler 2009; 15 (5): 571–579. doi: 10.1177/13524585 08102085.

10. Marrie RA, Gryba C. The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care 2013; 15 (3): 113–118. doi: 10.7224/1537-2073.2012-048.

11. Nytrova P, Kleinova J, Preiningerova Lizrova J et al. Neuromyelitis optiva a poruchy jejího širšího spektra – retrospektivní analýza klinických a paraklinických nálezů. Cesk Slov Neurol N 2015; 78/111 (1): 72–77. doi: 10.14735/amcsnn201572.

12. Glisson CHC. Neuromyelitis optica spectrum disorders. Available from URL: https: //www.uptodate.com/contents/neuromyelitis-optica-spectrum-disorders.

13. Weinshenkers BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc 2017; 92 (4): 663–679. doi: 10.1016/j.mayocp.2016.12.014.

14. Wingerchuk DM, Hogancamp WF, O‘Brien PC et al. The clinical course of neuromyelitis optica (Devic‘s syndrome). Neurology 1999; 53 (5): 1107–1114. doi: 10.1212/wnl.53.5.1107.

15. Ratchford JN, Quigg ME, Conger A et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009; 73 (4): 302–308. doi: 10.1212/WNL.0b013e3181af78b8.

16. Kitley J, Leite MI, Nakashima I. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135 (Pt 6): 1834–1849. doi: 10.1093/brain/aws109.

17. Wingerchuk DM, Lennon VA, Pittock SJ et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66 (10): 1485–1489. doi: 10.1212/01.wnl.0000216139.44259.74.

18. Flanagan EP, Weinshenker BG, Krecke KN et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015; 72 (1): 81–87. doi: 10.1001/jamaneurol.2014.2137.

19. He Z, Ren M, Wang X et al. Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2017; 13: 1–3. doi: 10.1016/j.msard.2017.01.011.

20. Netravathi M, Saini J, Mahadevan A et al. Is pruritus an indicator of aquaporin-positive neuromyelitis optica? Mult Scler 2017; 23 (6): 810–817. doi: 10.1177/1352458516665497.

21. Han J, Yang MG, Zhu J et al. Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations. Neuropsychiatr Dis Treat 2017; 13: 2653–2660. doi: 10.2147/NDT.S147360.

22. Wingerchuk DM, Banwell B, Bennett JL. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (2): 177–189. doi: 10.1212/WNL.0000000000001729.

23. Shosha E, Dubey D, Palace J. Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology 2018; 91 (17): e1642–e1651. doi: 10.1212/WNL.0000000000006392.

24. Kallollimath P, Gujjar A, Patil M. Symptomatic narcolepsy as a presenting feature of neuromyelitis optica. Ann Indian Acad Neurol 2018; 21 (2): 156–158. doi: 10.4103/aian.AIAN_74_18.

25. Kanbayashi T, Shimohata T, Nakashima I et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009; 66 (12): 1563–1566. doi: 10.1001/archneurol.2009.264.

26. Crnošija L, Krbot Skorić M et al. Autonomic dysfunction in people with neuromyelitis optica spectrum disorders. Mult Scler 2020; 26 (6): 688–695. doi: 10.1177/1352458519837703.

27. Barun B, Adamec I, Lovrić M et al. Postural orthostatic tachycardia syndrome: additional phenotypic feature of neuromyelitis optica spectrum disorder. Neurol Sci 2014; 35 (10): 1623–1625. doi: 10.1007/s10072-014-1810-9.

28. Kim W, Kim SH, Huh SY et al. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012; 2012: 735486. doi: 10.1155/2012/735486.

29. Kim W, Kim SH, Lee SH et al. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler. 2011; 17 (9): 1107–1112. doi: 10.1177/1352458511404917.

30. Jarius S, Paul F, Aktas O et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018; 15 (1): 134. doi: 10.1186/s12974-018-1144-2.

31. Seze de J. MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease? Brain 2017; 140 (12): 3072–3075. doi: 10.1093/brain/awx292.

32. Ishii N, Mochizuki H, Takahashi T et al. A case of simultaneous neuromyelitis optica spectrum disorder and subacute combined degeneration. Neurol Sci 2013; 34 (10): 1819–1821. doi: 10.1007/s10072-013-1301-4.

33. Jarius S, Paul F, Ruprecht K et al. Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol 2012; 259 (12): 2743–2745. doi: 10.1007/s00415-012-6677-1.

34. Sato D, Fujihara K. Atypical presentations of neuromyelitis optica. Arq Neuropsiquiatr 2011; 69 (5): 824–828. doi: 10.1590/s0004-282x2011000600019.